ITC's strategic plan for Open Science 2021-2025:towards an open future

Open Science (OS) is an umbrella term comprising principles to increase the transparency of research. Besides Open Access to scientific articles, these principles contain public availability of reusable methods (e.g., code and tools), data, and educational materials. This document outlines a plan to achieve the transition towards OS. ITC’s Strategic Plan for OS 2021-2025 - Towards an Open Future contains five initiatives: 1.OS at ITC aims to provide guidelines and OS capacity development to address the obstacles ITC researchers encounter when doing OS. 2.The ITC Knowledge Hub will provide services and tools to access, create, and publish open research, including scientific results based on qualitative/quantitative analyses using computational workflows. 3.Open Educational Resources will be addressed by exploring options to realise Open Educational Resources at ITC and providing lecturers with guidelines and support to create them. 4.The OS Community Twente serves as an inter-disciplinary, bottom-up community to promote, learn, share, and discuss OS practices. 5.Research & Funding aims to address challenges in OS through innovative developments and user studies. A further output is to generate funding to realise the ambitious aims presented in the plan. For a successful OS transition, the initiatives aim to address the Rewards & Recognition system, valorise Sharing & Collaboration, develop OS Knowledge & Skills, and foster Cultural change & Societal impact

Chronic treatment with ivabradine does not affect cardiovascular autonomic control in rats

A low resting heart rate (HR) would be of great benefit in cardiovascular diseases. Ivabradine-a novel selective inhibitor of hyperpolarization-activated cyclic nucleotide gated (HCN) channels- has emerged as a promising HR lowering drug. Its effects on the autonomic HR control are little known. This study assessed the effects of chronic treatment with ivabradine on the modulatory, reflex and tonic cardiovascular autonomic control and on the renal sympathetic nerve activity (RSNA). Male Wistar rats were divided in 2 groups, receiving intraperitoneal injections of vehicle (VEH) or ivabradine (IVA) during 7 or 8 consecutive days. Rats were submitted to vessels cannulation to perform arterial blood pressure (AP) and HR recordings in freely moving rats. Time series of resting pulse interval and systolic AP were used to measure cardiovascular variability parameters. We also assessed the baroreflex, chemoreflex and the Bezold-Jarish reflex sensitivities. To better evaluate the effects of ivabradine on the autonomic control of the heart, we performed sympathetic and vagal autonomic blockade. As expected, ivabradine-treated rats showed a lower resting (VEH: 362 \ufffd 16 bpm vs. IVA: 260 \ufffd 14 bpm, p = 0.0005) and intrinsic HR (VEH: 369 \ufffd 9 bpm vs. IVA: 326 \ufffd 11 bpm, p = 0.0146). However, the chronic treatment with ivabradine did not change normalized HR spectral parameters LF (nu) (VEH: 24.2 \ufffd 4.6 vs. IVA: 29.8 \ufffd 6.4; p > 0.05); HF (nu) (VEH: 75.1 \ufffd 3.7 vs. IVA: 69.2 \ufffd 5.8; p > 0.05), any cardiovascular reflexes, neither the tonic autonomic control of the HR (tonic sympathovagal index; VEH: 0.91\ufffd 0.02 vs. IVA: 0.88 \ufffd 0.03, p = 0.3494). We performed the AP, HR and RSNA recordings in urethane-anesthetized rats. The chronic treatment with ivabradine reduced the resting HR (VEH: 364 \ufffd 12 bpm vs. IVA: 207 \ufffd 11 bpm, p < 0.0001), without affecting RSNA (VEH: 117 \ufffd 16 vs. IVA: 120 \ufffd 9 spikes/s, p = 0.9100) and mean arterial pressure (VEH: 70 \ufffd 4 vs. IVA: 77 \ufffd 6 mmHg, p = 0.3293). Our results suggest that, in health rats, the long-term treatment with ivabradine directly reduces the HR without changing the RSNA modulation and the reflex and tonic autonomic control of the heart

Mapping child growth failure across low- and middle-income countries

Childhood malnutrition is associated with high morbidity and mortality globally1. Undernourished children are more likely to experience cognitive, physical, and metabolic developmental impairments that can lead to later cardiovascular disease, reduced intellectual ability and school attainment, and reduced economic productivity in adulthood2. Child growth failure (CGF), expressed as stunting, wasting, and underweight in children under five years of age (0�59 months), is a specific subset of undernutrition characterized by insufficient height or weight against age-specific growth reference standards3�5. The prevalence of stunting, wasting, or underweight in children under five is the proportion of children with a height-for-age, weight-for-height, or weight-for-age z-score, respectively, that is more than two standard deviations below the World Health Organization�s median growth reference standards for a healthy population6. Subnational estimates of CGF report substantial heterogeneity within countries, but are available primarily at the first administrative level (for example, states or provinces)7; the uneven geographical distribution of CGF has motivated further calls for assessments that can match the local scale of many public health programmes8. Building from our previous work mapping CGF in Africa9, here we provide the first, to our knowledge, mapped high-spatial-resolution estimates of CGF indicators from 2000 to 2017 across 105 low- and middle-income countries (LMICs), where 99 of affected children live1, aggregated to policy-relevant first and second (for example, districts or counties) administrative-level units and national levels. Despite remarkable declines over the study period, many LMICs remain far from the ambitious World Health Organization Global Nutrition Targets to reduce stunting by 40 and wasting to less than 5 by 2025. Large disparities in prevalence and progress exist across and within countries; our maps identify high-prevalence areas even within nations otherwise succeeding in reducing overall CGF prevalence. By highlighting where the highest-need populations reside, these geospatial estimates can support policy-makers in planning interventions that are adapted locally and in efficiently directing resources towards reducing CGF and its health implications. © 2020, The Author(s)